drugset / Trial / NCT01083615
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine if the addition of study drug (custirsen) can provide durable pain palliation for castrate resistant prostate cancer patients receiving docetaxel retreatment or cabazitaxel as a second line therapy.
Timeline
- Start
- 2010-03
- Primary completion
- 2013-03
- Completion
- 2013-03
Outcome
Outcome not reported
Stopped (Enrollment): “Unable to enroll due to criteria for stable baseline pain”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | custirsen | Antisense oligonucleotide | 640 mg | — |
| Background | Cabazitaxel | Other / unclassified | 25 mg/m2 | — |
| Background | Docetaxel | Small molecule | 75 mg/m2 | — |
| Background | Prednisone | Other / unclassified | — | Oral |